Anaxiom Reports Initial First-in-Human Clinical Results for Novel Minimally Invasive Obesity Device, Progresses Toward U.S. Early Feasibility Study Anaxiom Corporation, a clinical-stage innovator focused on developing minimally invasive solutions for obesity treatment, has announced the successful completion of a 12-patient…
GE HealthCare Doses First Patient in Phase 2/3 LUMINA Trial of Manganese-Based MRI Contrast Agent Under FDA Fast Track Status, Advancing Imaging Innovation Pipeline GE HealthCare has announced a major clinical milestone with the dosing of the first patient in…
Merz Group Participates in the “Made for Germany” Initiative The Merz Group has taken a significant step in reinforcing its commitment to Germany’s industrial and economic future by joining the “Made for Germany” initiative, a prominent alliance of 129 leading…
Late-Breaking PRESERVE Trial Findings Assess XVIVO’s HOPE Preservation Strategy in Heart Transplantation XVIVO, a global medical technology company specializing in organ preservation and transplantation, has announced encouraging late-breaking preliminary results from its PRESERVE Trial (NCT05881278). The study evaluates hypothermic oxygenated…
Vistagen Secures FDA “Study May Proceed” Clearance for Refisolone IND, Advancing Phase 2 Development in Menopause-Related Vasomotor Symptoms Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company focused on advancing neuroscience through its proprietary nose-to-brain neurocircuitry platform, has announced a key…
PureTech Reports Positive Phase 1b Topline Data for LYT-200 in Relapsed/Refractory High-Risk MDS and AML PureTech Health plc, a hub-and-spoke biotherapeutics company focused on transforming scientific innovation into value and advancing novel therapies across a range of serious diseases, has…
FDA Grants Approval to Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir) Merck & Co. (NYSE: MRK), known as MSD outside the United States and Canada, has announced that the U.S. Food and Drug Administration has approved IDVYNSO, a novel once-daily, two-drug single-tablet regimen…
Genentech’s Enspryng (Satralizumab) Cuts Relapse Risk by 68%, Showing Promise as a Potential First Treatment for MOGAD Genentech, a member of the Roche Group, has announced compelling new results from its Phase III METEOROID clinical trial evaluating Enspryng (satralizumab) in…
n-Lorem Foundation Reaches Key Milestone with 50th Nano-Rare Patient Treated Using a Personalized Antisense Oligonucleotide Therapy n-Lorem, a nonprofit foundation dedicated to advancing precision genetic medicine for individuals with ultra-rare conditions, has reached a significant milestone with the treatment of…
Annals of Internal Medicine Reports One-Year Findings from LivaNova’s OSPREY Clinical Trial in Obstructive Sleep Apnea LivaNova PLC (Nasdaq: LIVN) has announced the publication of comprehensive 12-month results from its landmark OSPREY randomized controlled trial (RCT) in the prestigious Annals…
Neurogene Announces Christy Shafer as Chief Commercial Officer and Appoints Christine Mikail, J.D., to Its Board Neurogene Inc. has announced key leadership additions as it advances its mission to develop transformative therapies for rare neurological diseases. The company has appointed…
Bicycle Therapeutics Shares Pipeline Update on Nuzefatide Pevedotin and EphA2 Programs at AACR 2026 Bicycle Therapeutics has unveiled a comprehensive set of updates from its EphA2-targeting oncology pipeline at the American Association for Cancer Research Annual Meeting, highlighting growing clinical…